Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EBIT (2022 - 2025)

Stoke Therapeutics has reported EBIT over the past 4 years, most recently at -$61.4 million for Q4 2025.

  • For Q4 2025, EBIT fell 350.0% year-over-year to -$61.4 million; the TTM value through Dec 2025 reached -$20.6 million, up 79.69%, while the annual FY2025 figure was -$20.6 million, 79.69% up from the prior year.
  • EBIT for Q4 2025 was -$61.4 million at Stoke Therapeutics, down from -$43.1 million in the prior quarter.
  • Over five years, EBIT peaked at $111.2 million in Q1 2025 and troughed at -$61.4 million in Q4 2025.
  • A 4-year average of -$21.3 million and a median of -$27.3 million in 2023 define the central range for EBIT.
  • On a YoY basis, EBIT climbed as much as 492.08% in 2025 and fell as far as 350.0% in 2025.
  • Year by year, EBIT stood at -$27.2 million in 2022, then fell by 8.87% to -$29.6 million in 2023, then soared by 53.85% to -$13.7 million in 2024, then crashed by 350.0% to -$61.4 million in 2025.
  • Business Quant data shows EBIT for STOK at -$61.4 million in Q4 2025, -$43.1 million in Q3 2025, and -$27.3 million in Q2 2025.